Alector announces first participant dosed in phase 2 study evaluating al002 in individuals with early alzheimer's disease

South san francisco, calif., jan. 25, 2021 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in invoke-2, a phase 2 clinical study evaluating the efficacy and safety of al002 in slowing disease progression in individuals with early alzheimer's disease. al002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (trem2), a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia, which serve as the immune cells in the brain. the al002 clinical program is being developed in collaboration with abbvie.
ALEC Ratings Summary
ALEC Quant Ranking